Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
headphones
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

PVI, PeerView Institute for Medical Education

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
bookmark
Share icon

All episodes

Best episodes

Top 10 PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast Episodes

Goodpods has curated a list of the 10 best PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast episode by adding your comments to the episode page.

Go online to PeerView.com/XEJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple new drug approvals and positive clinical trial outcomes have set the stage for the wider integration of novel therapeutics across the treatment spectrum of hepatocellular carcinoma (HCC). These developments have established multiple targeted and immunotherapy agents as options in advanced disease while also mapping potential future applications in intermediate stage HCC and beyond. Future care will depend on the successful integration of newer tyrosine kinase inhibitor (TKI)-based approaches with established and emerging immune checkpoint inhibitors across patient populations and lines of therapy. This PeerView “How I Think, How I Treat” activity, based on a symposium held during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, offers an inside look at how experts translate important new data and navigate the current HCC landscape in order to provide the most benefit for their patients. This activity also features important insights on how to utilize newly approved TKIs and checkpoint inhibitors across disease and treatment settings, as well as provides expert thoughts on the next wave of emerging solutions that leverage the power of novel therapies across the continuum of HCC. Upon completion of this activity, participants should be better able to: Summarize emerging clinical evidence on the use of novel systemic treatments, including targeted and immunotherapeutic agents, in a range of HCC treatment settings and populations, Apply recent safety and efficacy data on targeted therapies into clinical practice to enhance aspects of HCC care, including treatment sequencing and managing treatment-related adverse events, Integrate immunotherapeutic strategies for the management of patients with advanced HCC, including through optimal treatment selection and via management of immune-related adverse events, Identify innovative treatment strategies currently being assessed in clinical trials across the spectrum of HCC, such as immunotherapy combinations, combinations of novel agents with locoregional therapies, and early transition to systemic treatment, among others.
bookmark
plus icon
share episode
Go online to PeerView.com/XHY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology and pediatric primary care discuss the management of patients with atopic dermatitis. A patient also joins the discussion to provide unique perspectives on living with atopic dermatitis and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Diagnose atopic dermatitis in individual patients based on recognition of clinical manifestations and application of current diagnostic criteria and guidelines, Describe the mechanisms of action and clinical profiles of new and emerging topical and systemic therapies for atopic dermatitis, Select appropriate treatments for patients with atopic dermatitis based on current guideline recommendations, the safety and efficacy of available treatment options, comorbidities, and burden of disease, Employ shared decision-making approaches to create individualized treatment plans for atopic dermatitis, Implement patient/caregiver education strategies to improve adherence to atopic dermatitis treatment (eg, managing application-site pain associated with topical therapies) and assess the effects of treatment on patient quality of life
bookmark
plus icon
share episode
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast - Monica Kraft, MD - The Latest Evidence on Treatment for Uncontrolled Persistent Asthma: Breaking News From Dallas
play

07/22/19 • 28 min

Go online to PeerView.com/GSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an asthma expert discusses the latest evidence and data on treatment for persistent asthma presented at the American Thoracic Society Conference 2019 in Dallas, Texas. Upon completion of this activity, participants should be better able to: Discuss the latest clinical data for the efficacy and safety of approved and emerging treatments for uncontrolled persistent asthma, Employ strategies to treat patients with uncontrolled persistent asthma in the context of late-breaking data and patient-, disease-, and therapy-related factors.
bookmark
plus icon
share episode
Go online to PeerView.com/XQR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses the role of novel therapeutic options in overcoming challenges associated with the management of patients with refractory rheumatoid arthritis. Upon completion of this activity, participants should be better able to: Recognize challenges associated with the management of refractory rheumatoid arthritis, Identify novel therapeutic options for rheumatoid arthritis in the context of mechanism of action, efficacy, and safety, Employ current evidence and expert recommendations into individualized treatment plans for patients with rheumatoid arthritis who have not achieved adequate disease control on previous therapies.
bookmark
plus icon
share episode
Go online to PeerView.com/EWW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Melanoma was the first clinical setting in which the use of immune checkpoint inhibitors was validated, leading to their rapid integration into the management of advanced disease. More recently, checkpoint inhibitors, based on phase 3 evidence, have claimed a role in the adjuvant setting. The future of adjuvant therapy for high-risk resectable melanoma is bright, but achieving optimal care will depend on close collaboration between oncologists and surgeons, as well as the identification of patients who are excellent candidates for immune-based adjuvant therapy. In this activity, based on a recent live symposium, experts in oncology get to the heart of why immunotherapy is a rational and potent management strategy for patients with high-risk, resected melanoma, offer insights into the key studies that validated adjuvant immunotherapy in resectable disease, as well as clarify what the evidence from these trials means for the practice of surgical oncology. The panel of leading experts also synthesizes the clinical experience with adjuvant checkpoint inhibition and detail practical patient identification, dosing, and safety considerations that will make a difference in how you manage your patients. Upon completion of this activity, participants should be better able to: Describe the clinical role and rationale for use of immune-based therapy in stage III, resectable melanoma, Cite updated efficacy and safety findings regarding immune checkpoint inhibitors as an adjuvant option in surgically resected melanoma, including high-risk stage III disease, Recommend the use of adjuvant immunotherapy for eligible patients with resectable stage III melanoma, Manage immune-related and immune-mediated adverse events in patients with melanoma treated with immunotherapy after surgical resection.
bookmark
plus icon
share episode
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast - Madan H. Jagasia, MBBS, MS, MMHC - Innovative Therapies in Post-Transplant GVHD: Personal Insights From the Patient CaseBook
play

04/05/19 • 48 min

Go online to PeerView.com/XYM860 to view the entire program with slides. This activity utilizes a “CaseBook” format, offering learners a collection of patient case scenarios from the experts’ personal repertoire paired with analyses of how the treatment landscape in acute and chronic graft-versus-host disease (GVHD) is evolving. Hematology-oncology and bone marrow transplant professionals take a deep dive into the underlying immunology of GVHD and the latest evidence with innovative therapeutics while also obtaining expert perspectives on the practical application of these advancements as prophylaxis or for treatment of acute and chronic, steroid–nonresponsive, and previously untreated GVHD. Upon completion of this activity, participants should be better able to: Describe the underlying immunology of post-transplant GVHD, and the rationale for and mechanisms of novel therapies in the management of GVHD, Discuss the latest evidence on novel therapies, including JAK 1/2 inhibitors, BTK inhibitors, and T-cell costimulation modulators, for prophylaxis or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HSCT setting, Apply the most optimal evidence-based strategies, including enrollment in clinical trials, for post-transplant GVHD care based on individual patient and disease characteristics.
bookmark
plus icon
share episode
Go online to PeerView.com/XNY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in chronic rhinosinusitis with nasal polyps discusses novel and emerging biologic therapies to improve the quality of life for patients with chronic rhinosinusitis with nasal polyps. Upon completion of this activity, participants should be better able to: Recognize the burden that chronic rhinosinusitis with nasal polyps (CRS/NP) on patient quality of life, Describe the pathophysiology of CRS/NP and its relevance to novel therapeutic targets, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRS/NP, Apply individualized treatment plans, including the use of targeted biologic therapy, for patients with CRS/NP inadequately controlled on standard therapy.
bookmark
plus icon
share episode
Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP
bookmark
plus icon
share episode
Go online to PeerView.com/EPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an asthma expert discusses advances in the understanding of the pathogenesis of asthma and novel targeted treatments that have been developed as a result. Strategies for identifying uncontrolled moderate-to-severe asthma patients who would benefit from these agents and clinical data for the currently available and emerging biologic therapies for asthma treatment are also discussed. Upon completion of this activity, participants should be better able to: Describe the economic impact and quality-of-life burden of moderate-to-severe asthma, Discuss the inflammatory mediators and mechanisms that provide the basis for the phenotypes and endotypes of severe asthma and their relevance to novel biologic therapies, Assess the latest clinical data with regard to efficacy and safety for currently available and emerging biologic therapies for the treatment of severe asthma, Apply treatment for patients with asthma based on symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapies
bookmark
plus icon
share episode
Go online to PeerView.com/GZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two melanoma experts engage in case-based discussions and scientific lecture segments on topics such as the selection of immunotherapy in metastatic disease, best practices for the use of adjuvant or neoadjuvant checkpoint blockade, and how future care will be defined by emerging science on novel immunotherapy combination approaches. Upon completion of this accredited CE activity, participants should be better able to: Cite current evidence and guideline recommendations for the use of immunotherapy in resectable stage III/IV melanoma and unresectable, metastatic disease, Summarize evidence on novel applications of immunotherapy in melanoma, including as neoadjuvant therapy, as an adjuvant option for stage II disease, or as part of novel combinatorial approaches, Integrate immunotherapy into the management of patients with resectable and unresectable melanoma, including those with BRAF-positive or BRAF-negative disease, Manage immune-related adverse events in patients with melanoma receiving immunotherapy across the spectrum of disease.
bookmark
plus icon
share episode

Show more best episodes

Toggle view more icon

FAQ

How many episodes does PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast have?

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast currently has 211 episodes available.

What topics does PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast cover?

The podcast is about Health & Fitness, Cme, Medicine, Immunology, Podcasts, Science and Medical Education.

What is the most popular episode on PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast?

The episode title 'Reynold A. Panettieri, Jr., MD - Improving Outcomes in Uncontrolled Moderate-to-Severe Asthma: Choosing the Right Treatment for the Right Patient' is the most popular.

What is the average episode length on PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast?

The average episode length on PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast is 55 minutes.

How often are episodes of PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast released?

Episodes of PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast are typically released every 2 days.

When was the first episode of PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast?

The first episode of PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast was released on Oct 31, 2018.

Show more FAQ

Toggle view more icon

Comments